Table 2.

Cases taken from the literature and clinician experience^a.

Baseline case	Study, year	Variations to baseline case for sensitivity analysis
Low-risk CESb	Finucane et al [22], 2020	Higher risk (1 additional symptom) Additional symptoms of cancer Additional symptoms of inflammatory condition
Low- to midrisk CES	Finucane et al [22], 2020	Higher risk (1 additional symptom) Additional symptoms of cancer Additional symptoms of inflammatory condition
Midrisk CES	Finucane et al [22], 2020	Higher risk (1 additional symptom) Additional symptoms of cancer Additional symptoms of inflammatory condition
High-risk CES	Finucane et al [22], 2020	Higher risk (1 additional symptom) Additional symptoms of cancer Additional symptoms of inflammatory condition
Low-risk fracture	Finucane et al [22], 2020	Higher risk (1 additional symptom) Additional symptoms of cancer Additional symptoms of inflammatory condition
Low- to midrisk fracture	Finucane et al [22], 2020	Higher risk (1 additional symptom) Additional symptoms of cancer Additional symptoms of inflammatory condition
Midrisk fracture	Finucane et al [22], 2020	Higher risk (1 additional symptom) Additional symptoms of cancer Additional symptoms of inflammatory condition
High-risk fracture	Finucane et al [22], 2020	Higher risk (1 additional symptom) Additional symptoms of cancer Additional symptoms of inflammatory condition
Low-risk malignancy	Finucane et al [22], 2020	Higher risk (1 additional symptom) Additional symptoms of inflammatory condition
Low- to midrisk malignancy	Finucane et al [22], 2020	Higher risk (1 additional symptom) Additional symptoms of inflammatory condition
Midrisk malignancy	Finucane et al [22], 2020	Higher risk (1 additional symptom) Additional symptoms of inflammatory condition
High-risk malignancy	Finucane et al [22], 2020	Higher risk (1 additional symptom) Additional symptoms of inflammatory condition
Low-risk infection	Finucane et al [22], 2020	Higher risk (1 additional symptom) Additional symptoms of cancer Additional symptoms of inflammatory condition
Low- to midrisk infection	Finucane et al [22], 2020	Higher risk (1 additional symptom) Additional symptoms of cancer Additional symptoms of inflammatory condition
Midrisk infection	Finucane et al [22], 2020	Higher risk (1 additional symptom) Additional symptoms of cancer Additional symptoms of inflammatory condition
High-risk infection	Finucane et al [22], 2020	Higher risk (1 additional symptom) Additional symptoms of cancer Additional symptoms of inflammatory condition
Inflammatory condition	Real case	Higher risk (1 additional symptom) Additional symptoms of cancer
Inflammatory condition	Real case	Higher risk (1 additional symptom) Additional symptoms of cancer
Nerve root condition	Jones and Rivett [27], 2018	Higher risk (1 additional symptom) Additional symptoms of cancer Additional symptoms of inflammatory condition

^aCases were modified as described for sensitivity analysis and assessed by an independent third party.

^bCES: cauda equina syndrome.